Jacek Pliszczyński
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacek Pliszczyński has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Beata Lagiewska
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
5 shared publications - Leszek Pączek
Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland
5 shared publications - Maciej Kosieradzki
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
5 shared publications - Janusz Wyzgał
Department of Nephrology Nursing, Medical University of Warsaw, Warsaw, Poland
3 shared publications A. Chmura
Transplantation Institute, the Medical University of Warsaw (W.R., R.S., A.C., J.P., J.W., T.C., B.L., J.W., L.P., M.L., A.G.), Warsaw, Poland
2 shared publicationsAgnieszka Jóźwik
Department of General and Transplantation Surgery, Warsaw Medical University, Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 8 March 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e949545
Two Cases of Successful Kidney Transplantation From a 39-Year-Old Male Deceased Donor With Marfan Syndrome: A Case Series
BACKGROUND Marfan syndrome is a multisystemic, autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene. It is associated with life-threatening complications, especially aortic aneurysms and dissections, and has a global prevalence of 1 in 3000-5000 individuals. Although kidney transplantation is the standard treatment for end-stage renal disease (ESRD), deceased kidney donors with Marfan syndrome remain uncommon due to concerns about connective tissue fragility. Emerging reports, however, indicate that kidneys from such donors may be safely used. This report describes 2 successful kidney transplantations from a 39-year-old male donor with confirmed Marfan syndrome. CASE REPORT Case 1. The donor died from subarachnoid hemorrhage and had a history of aortic arch replacement for aortic dissection. Both kidneys were retrieved from the retroperitoneal space, prepared according to standard protocols, and stored in University of Wisconsin Store Protect Plus organ preservation solution under static cold storage at 4°C. Case 2. A 59-year-old man with ESRD secondary to diabetic nephropathy underwent his first kidney transplantation. He was hemodialyzed with residual diuresis. The right kidney was transplanted without complications, and the recipient achieved immediate and stable graft function. Case 3. The second recipient was a 34-year-old man with ESRD due to vesicoureteral reflux and obstructive nephropathy, also on hemodialysis with preserved diuresis. Left kidney transplantation proceeded uneventfully. He experienced delayed graft function, which resolved with appropriate management, resulting in satisfactory renal recovery. CONCLUSIONS These cases support the growing evidence that kidneys from donors with Marfan syndrome can function effectively after transplantation. Such donors may represent a valuable and underutilized resource, with the potential to expand the kidney donor pool safely.
- 8 March 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e949545
Open AccessTwo Cases of Successful Kidney Transplantation From a 39-Year-Old Male Deceased Donor With Marfan Syndrome: A Case Series
BACKGROUND Marfan syndrome is a multisystemic, autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene. It is associated with life-threatening complications, especially aortic aneurysms and dissections, and has a global prevalence of 1 in 3000-5000 individuals. Although kidney transplantation is the standard treatment for end-stage renal disease (ESRD), deceased kidney donors with Marfan syndrome remain uncommon due to concerns about connective tissue fragility. Emerging reports, however, indicate that kidneys from such donors may be safely used. This report describes 2 successful kidney transplantations from a 39-year-old male donor with confirmed Marfan syndrome. CASE REPORT Case 1. The donor died from subarachnoid hemorrhage and had a history of aortic arch replacement for aortic dissection. Both kidneys were retrieved from the retroperitoneal space, prepared according to standard protocols, and stored in University of Wisconsin Store Protect Plus organ preservation solution under static cold storage at 4°C. Case 2. A 59-year-old man with ESRD secondary to diabetic nephropathy underwent his first kidney transplantation. He was hemodialyzed with residual diuresis. The right kidney was transplanted without complications, and the recipient achieved immediate and stable graft function. Case 3. The second recipient was a 34-year-old man with ESRD due to vesicoureteral reflux and obstructive nephropathy, also on hemodialysis with preserved diuresis. Left kidney transplantation proceeded uneventfully. He experienced delayed graft function, which resolved with appropriate management, resulting in satisfactory renal recovery. CONCLUSIONS These cases support the growing evidence that kidneys from donors with Marfan syndrome can function effectively after transplantation. Such donors may represent a valuable and underutilized resource, with the potential to expand the kidney donor pool safely.
- Open Access
- 2 July 2025
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 30, e949896
Vascular Challenges in Horseshoe Kidney Transplantation: A Case Report
BACKGROUND Horseshoe kidney is a rare congenital anomaly, occurring in approximately 1 in 400 to 1 in 1800 individuals. When considering transplantation, horseshoe kidneys present unique challenges due to vascular and urinary tract anomalies. They can be transplanted either as a whole, en bloc unit or as 2 separate, split fragments. The complexities in vascular and urinary reconstruction require careful consideration to ensure successful transplantation. CASE REPORT We present a case involving the transplantation of a horseshoe kidney from a deceased 36-year-old male donor with confirmed brain death due to intracerebral bleeding. The kidney had a complex vascular arrangement, with 7 arteries, 2 veins, and 2 ureters. A surgical division and vascular reconstruction were performed. The kidney fragments were successfully transplanted into 64- and 65-year-old male recipients. Both grafts exhibited excellent reperfusion, and at 2-month follow-up, both patients demonstrated satisfactory graft function, without dialysis or acute rejection episodes. CONCLUSIONS In light of the ongoing shortage of kidney grafts, horseshoe kidneys represent a valuable yet challenging option for transplantation. While vascular and urinary tract anomalies can complicate their use, this case illustrates that, with meticulous surgical technique, horseshoe kidney transplantation can be both viable and safe. Nevertheless, the absence of standardized guidelines for splitting techniques and pre-procurement anatomical assessment underscores the need for further research and consensus in this area.
- 2 July 2025
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 30, e949896
Open AccessVascular Challenges in Horseshoe Kidney Transplantation: A Case Report
BACKGROUND Horseshoe kidney is a rare congenital anomaly, occurring in approximately 1 in 400 to 1 in 1800 individuals. When considering transplantation, horseshoe kidneys present unique challenges due to vascular and urinary tract anomalies. They can be transplanted either as a whole, en bloc unit or as 2 separate, split fragments. The complexities in vascular and urinary reconstruction require careful consideration to ensure successful transplantation. CASE REPORT We present a case involving the transplantation of a horseshoe kidney from a deceased 36-year-old male donor with confirmed brain death due to intracerebral bleeding. The kidney had a complex vascular arrangement, with 7 arteries, 2 veins, and 2 ureters. A surgical division and vascular reconstruction were performed. The kidney fragments were successfully transplanted into 64- and 65-year-old male recipients. Both grafts exhibited excellent reperfusion, and at 2-month follow-up, both patients demonstrated satisfactory graft function, without dialysis or acute rejection episodes. CONCLUSIONS In light of the ongoing shortage of kidney grafts, horseshoe kidneys represent a valuable yet challenging option for transplantation. While vascular and urinary tract anomalies can complicate their use, this case illustrates that, with meticulous surgical technique, horseshoe kidney transplantation can be both viable and safe. Nevertheless, the absence of standardized guidelines for splitting techniques and pre-procurement anatomical assessment underscores the need for further research and consensus in this area.
- Open Access
- 22 September 2021
- Published by IntechOpen
Surgical Treatment of Wounds Using Stem Cells in Epidermolysis Bullosa (EB)
Epidermolysis bullosa (EB) is a group of hereditary skin diseases, or genodermatoses, characterized by the formation of severe, chronic blisters with painful and life-threatening complications. Despite the previous and ongoing progress in the field, there are still no effective causative treatments for EB. The treatment is limited to relieving symptoms, which—depending on disease severity—may involve skin (blisters, poorly healing wounds caused by the slightest mechanical stimuli, contractures, scarring, pseudosyndactyly) and internal organ abnormalities (esophageal, pyloric, or duodenal atresia; renal failure; and hematopoietic abnormalities). The last decade saw a series of important discoveries that paved the way for new treatment methods, including gene therapy, bone marrow transplantation, cell therapy (allogenic fibroblasts, mesenchymal stem cells [MSCs], and clinical use of induced pluripotent stem cells. Tissue engineering experts are attempting to develop skin-like structures that can facilitate the process of healing to promote skin reconstruction in injuries that are currently incurable. However, this is incredibly challenging, due to the complex structure and the many functions of the skin. Below, we characterize EB and present its potential treatment methods. Despite the cure for EB being still out of reach, recent data from animal models and initial clinical trials in humans have raised patients’, clinicians’, and researchers’ expectations. Consequently, modifying the course of the disease and improving the quality of life have become possible. Moreover, the conclusions drawn based on EB treatment may considerably improve the treatment of other genetic diseases.
- 22 September 2021
- Published by IntechOpen
Open AccessSurgical Treatment of Wounds Using Stem Cells in Epidermolysis Bullosa (EB)
Epidermolysis bullosa (EB) is a group of hereditary skin diseases, or genodermatoses, characterized by the formation of severe, chronic blisters with painful and life-threatening complications. Despite the previous and ongoing progress in the field, there are still no effective causative treatments for EB. The treatment is limited to relieving symptoms, which—depending on disease severity—may involve skin (blisters, poorly healing wounds caused by the slightest mechanical stimuli, contractures, scarring, pseudosyndactyly) and internal organ abnormalities (esophageal, pyloric, or duodenal atresia; renal failure; and hematopoietic abnormalities). The last decade saw a series of important discoveries that paved the way for new treatment methods, including gene therapy, bone marrow transplantation, cell therapy (allogenic fibroblasts, mesenchymal stem cells [MSCs], and clinical use of induced pluripotent stem cells. Tissue engineering experts are attempting to develop skin-like structures that can facilitate the process of healing to promote skin reconstruction in injuries that are currently incurable. However, this is incredibly challenging, due to the complex structure and the many functions of the skin. Below, we characterize EB and present its potential treatment methods. Despite the cure for EB being still out of reach, recent data from animal models and initial clinical trials in humans have raised patients’, clinicians’, and researchers’ expectations. Consequently, modifying the course of the disease and improving the quality of life have become possible. Moreover, the conclusions drawn based on EB treatment may considerably improve the treatment of other genetic diseases.
- 14 March 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1691-1696
Results of Renal Transplant From Deceased Anti-hepatitis C Virus Donors, Poland 1998-2012
- 14 March 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1691-1696
Results of Renal Transplant From Deceased Anti-hepatitis C Virus Donors, Poland 1998-2012
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (1) , 13-27
The epidemiology of hepatocellular cancer in Poland
Introduction This article summarize the available data on hepatocellular carcinoma (HCC) epidemiology in Poland. Data regarding the HCC incidence rate are divergent. Statistical data presented by NFZ appear more credible in that matter than data published by the Polish Oncology Center (POC)....
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (1) , 13-27
Open AccessThe epidemiology of hepatocellular cancer in Poland
Introduction This article summarize the available data on hepatocellular carcinoma (HCC) epidemiology in Poland. Data regarding the HCC incidence rate are divergent. Statistical data presented by NFZ appear more credible in that matter than data published by the Polish Oncology Center (POC)....
- 1 August 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101, S122
Complete Blood Count of Deceased Donors and the Results of Liver Transplantation
Evaluating donor characteristics is mandatory for the recipients’ safety and aiding predicting outcomes. The aim was to assess whether abnormalities in complete blood count (CBC) of DBD liver donor present risk factors. Early and long-term results [1-year recipient (1RS+/1RS-) and graft (1GS+/1GS-) survival, 5-year recipient (5RS+/5RS-) and graft (5GS+/5GS-) survival rates] of liver transplantation were evaluated in connection with donor CBC [HGB (g/dl), HCT (%), WBC(k/mm3), PLT(k/mm3)] respectively for 2804 transplantations in the years 1998‐2013 and 1724 in the years 1998‐2009. Data originated from Poltransplant’s records. Figure.1 1. Abnormalities in donor CBC do not influence the early and long-term recipient survival. 2.PLT does not affect the early and long-term transplant outcomes. 3.WBC affects early and late graft survival; reaches lower values in donors providing recipients with at least 1 and 5-year graft function, possibly because of the corresponding risk of infection transmission. 4.Significant deviations of HGB and HCT in groups of grafts that survived and not survived five years, do not display clinical justification.
- 1 August 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101, S122
Complete Blood Count of Deceased Donors and the Results of Liver Transplantation
Evaluating donor characteristics is mandatory for the recipients’ safety and aiding predicting outcomes. The aim was to assess whether abnormalities in complete blood count (CBC) of DBD liver donor present risk factors. Early and long-term results [1-year recipient (1RS+/1RS-) and graft (1GS+/1GS-) survival, 5-year recipient (5RS+/5RS-) and graft (5GS+/5GS-) survival rates] of liver transplantation were evaluated in connection with donor CBC [HGB (g/dl), HCT (%), WBC(k/mm3), PLT(k/mm3)] respectively for 2804 transplantations in the years 1998‐2013 and 1724 in the years 1998‐2009. Data originated from Poltransplant’s records. Figure.1 1. Abnormalities in donor CBC do not influence the early and long-term recipient survival. 2.PLT does not affect the early and long-term transplant outcomes. 3.WBC affects early and late graft survival; reaches lower values in donors providing recipients with at least 1 and 5-year graft function, possibly because of the corresponding risk of infection transmission. 4.Significant deviations of HGB and HCT in groups of grafts that survived and not survived five years, do not display clinical justification.
- 1 August 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101, S128
Results of Renal Transplant from Deceased Anti-HCV Positive Donors, Poland 1998‐2012
Kidney transplant (kTx) is the best method of renal insufficiency treatment. In dialyzed, mortality rises along the time on dialysis. There is a continuing shortage of organs for transplantation, hence a propensity to expand the donor pool with extended criteria donors, anti-HCV(+) included. In the above case a transmission of HCV genotype to recipient is present. It has been proven that contamination with more than one HCV genotype did not worsen kTx outcomes. There are 2,6% anti-HCV(+) donors in Poland. Utilization is only possible in case of anti-HCV(+) and anti-HCV RNA(+) recipients. Retrospective analysis covered 8675 deceased donors (1998‐2012 Polish data from “Poltransplant”). The early (after 12months) and late (after 60) graft and patient survival was assessed in kTx recipients, with documented (11410/12867) recipient and donor data spanning at least 1 year after kTx. 7016 kTx recipients with known anti-HCV status were included in comprehensive analysis, according to anti-HCV profile of recipient and donor. The results are in absolute and % values, p (<0.05) assessed with chi-square test. 12m survival: (R)recipient (95%), (G)graft (89%), total; R (95% vs 89%, p=0.0004), G (88 vs 79, p=0,0005) in HCV(−) to HCV(+/−) vs HCV(+) to HCV(+); R (95 vs 94, p=0.2), G (88 vs 83, p=0.0003), HCV(−) to HCV(−) vs HCV(−) to HCV(+); R (93 vs 95, p=0.004), G (82 vs 89, p<0.0001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (95 vs 89, p<0.0003), G (88 vs 79, p=0.0002) in HCV(−) to HCV(−) vs HCV(+) vs HCV (+)60m survival: R (86%), G (75%), total; R (84 vs 88, p=0.01), G (63 vs 71, p=0.001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (88 vs 80, p=0.003) in HCV(−) to HCV(−) vs HCV(+) to HCV(+) bhh. Worst anti-HCV serological profile was HCV(+) to HCV(+), although transplanting HCV(+) to HCV(+) did not worsen outcomes in that group. Worse kTx outcomes of HCV (+) over HCV(−) donors can be attributed to HCV(+) status of the recipient.
- 1 August 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101, S128
Results of Renal Transplant from Deceased Anti-HCV Positive Donors, Poland 1998‐2012
Kidney transplant (kTx) is the best method of renal insufficiency treatment. In dialyzed, mortality rises along the time on dialysis. There is a continuing shortage of organs for transplantation, hence a propensity to expand the donor pool with extended criteria donors, anti-HCV(+) included. In the above case a transmission of HCV genotype to recipient is present. It has been proven that contamination with more than one HCV genotype did not worsen kTx outcomes. There are 2,6% anti-HCV(+) donors in Poland. Utilization is only possible in case of anti-HCV(+) and anti-HCV RNA(+) recipients. Retrospective analysis covered 8675 deceased donors (1998‐2012 Polish data from “Poltransplant”). The early (after 12months) and late (after 60) graft and patient survival was assessed in kTx recipients, with documented (11410/12867) recipient and donor data spanning at least 1 year after kTx. 7016 kTx recipients with known anti-HCV status were included in comprehensive analysis, according to anti-HCV profile of recipient and donor. The results are in absolute and % values, p (<0.05) assessed with chi-square test. 12m survival: (R)recipient (95%), (G)graft (89%), total; R (95% vs 89%, p=0.0004), G (88 vs 79, p=0,0005) in HCV(−) to HCV(+/−) vs HCV(+) to HCV(+); R (95 vs 94, p=0.2), G (88 vs 83, p=0.0003), HCV(−) to HCV(−) vs HCV(−) to HCV(+); R (93 vs 95, p=0.004), G (82 vs 89, p<0.0001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (95 vs 89, p<0.0003), G (88 vs 79, p=0.0002) in HCV(−) to HCV(−) vs HCV(+) vs HCV (+)60m survival: R (86%), G (75%), total; R (84 vs 88, p=0.01), G (63 vs 71, p=0.001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (88 vs 80, p=0.003) in HCV(−) to HCV(−) vs HCV(+) to HCV(+) bhh. Worst anti-HCV serological profile was HCV(+) to HCV(+), although transplanting HCV(+) to HCV(+) did not worsen outcomes in that group. Worse kTx outcomes of HCV (+) over HCV(−) donors can be attributed to HCV(+) status of the recipient.
- 1 October 2014
- Published by Elsevier in Human Immunology
- Vol. 75, 74
P037
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 437-438
Lack of C1q Reactivity in Post-LVAD Patient Sera.
- 1 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 437-438
Lack of C1q Reactivity in Post-LVAD Patient Sera.